Seminars in hematology最新文献_第3页

Smoldering multiple myeloma: Integrating biology and risk into management. 燃烧性多发性骨髓瘤：将生物学和风险纳入管理。

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-18 DOI: 10.1053/j.seminhematol.2024.10.002

Roshani Patel, Elizabeth Hill, Madhav Dhodapkar

引用次数: 0

The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges. 1q 异常在多发性骨髓瘤中的作用：基因组学见解、临床意义和治疗挑战。

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-05 DOI: 10.1053/j.seminhematol.2024.10.001

Zachary M Avigan, Constantine S Mitsiades, Alessandro Laganà

引用次数: 0

CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies CARs 勇往直前：CAR T 细胞疗法在血液恶性肿瘤早期治疗过程中的发展。

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.08.005

Omar Castaneda Puglianini , Julio C. Chavez

引用次数: 0

CAR T-cell therapy comes of age: Introductory editorial for the special issue CAR T 细胞疗法时代的到来：特刊序言

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.10.003

Jennifer N. Brudno MD

引用次数: 0

The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL 多行不义必自毙--研究嵌合抗原受体T细胞疗法在B细胞ALL中的异基因造血干细胞移植的作用。

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.08.004

Michelle Choe MD , Corinne Summers MD

引用次数: 0

The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19 曲折的道路：COVID-19时代CAR-T和其他新型采纳性细胞疗法的传染病注意事项。

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.08.002

Kanal Singh , Joseph M. Rocco , Veronique Nussenblatt

{"title":"The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19","authors":"Kanal Singh , Joseph M. Rocco , Veronique Nussenblatt","doi":"10.1053/j.seminhematol.2024.08.002","DOIUrl":"10.1053/j.seminhematol.2024.08.002","url":null,"abstract":"<div><div>Adoptive cellular therapies (ACT) are novel, promising treatments for life-threatening malignancies. In addition to the better known chimeric antigen receptor (CAR) T cells, ACTs include tumor infiltrating lymphocytes (TIL), cancer antigen-specific T cell receptors (TCRs), and CAR-NK (natural killer) cells. In key historic milestones, several adoptive therapies recently received FDA approvals, including 6 CAR-T products for the treatment of hematologic malignancies and the first TIL therapy for the treatment for metastatic melanoma. The rapid pace of clinical trials in the field and the discoveries they provide are ushering in a new era of cancer immunotherapy. However, the potential complications of these therapies are still not fully understood. In particular, patients receiving ACT may be at increased risk for severe infections due to immunocompromise resulting from their underlying malignancies, which are further compounded by the immune derangements that develop in the setting of cellular immunotherapy and/or the preconditioning treatment needed to enhance ACT efficacy. Moreover, these treatments are being readily implemented at a time following the height of the COVID-19 pandemic, and it remains unclear what additional risks these patients may face from SARS-CoV-2 and similar infections. Here, we examine the evidence for infectious complications with emerging adoptive therapies, and provide a focused review of the epidemiology, complications, and clinical management for COVID-19 in CAR-T recipients to understand the risk this disease may pose to recipients of other forms of ACT.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 5","pages":"Pages 321-332"},"PeriodicalIF":5.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

outside front cover, PMS 8883 metallic AND 4/C 封面外侧，PMS 8883 金属色和 4/C

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/S0037-1963(24)00114-8

引用次数: 0

Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma? 加快 CAR-T/NK 疗法的普及--AlloCARs 和快速制造平台是改善多发性骨髓瘤治疗普及的必由之路吗？

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.09.001

Sridevi Rajeeve , Abhinav Hoskote , Sham Mailankody

引用次数: 0

Tuning CAR T-cell therapies for efficacy and reduced toxicity 调整 CAR T 细胞疗法，提高疗效并降低毒性

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.07.003

Danielle Blud , Patricia Rubio-Reyes , Rachel Perret , Robert Weinkove

{"title":"Tuning CAR T-cell therapies for efficacy and reduced toxicity","authors":"Danielle Blud , Patricia Rubio-Reyes , Rachel Perret , Robert Weinkove","doi":"10.1053/j.seminhematol.2024.07.003","DOIUrl":"10.1053/j.seminhematol.2024.07.003","url":null,"abstract":"<div><div>Chimeric antigen receptor (CAR) T-cell therapies are a standard of care for certain relapsed or refractory B-cell cancers. However, many patients do not respond to CAR T-cell therapy or relapse later, short- and long-term toxicities are common, and current CAR T-cell therapies have limited efficacy for solid cancers. The gene engineering inherent in CAR T-cell manufacture offers an unprecedented opportunity to control cellular characteristics and design products that may overcome these limitations. This review summarises available methods to “tune” CAR T-cells for optimal efficacy and safety. The components of a typical CAR, and the modifications that can influence CAR T-cell function are discussed. Methods of engineering passive, inducible or autonomous control mechanisms into CAR T-cells, allowing selective limitation or enhancement of CAR T-cell activity are reviewed. The impact of manufacturing processes on CAR T-cell function are considered, including methods of limiting CAR T-cell terminal differentiation and exhaustion, and the use of specific T-cell subsets as the CAR T starting material. We discuss the use of multicistronic transgenes and multiplexed gene editing. Finally, we highlight the need for innovative clinical trial designs if we are to make the most of the opportunities offered by CAR T-cell therapies.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 5","pages":"Pages 333-344"},"PeriodicalIF":5.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141713143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

License for a CAR T: Examining patient eligibility CAR T 许可：审查患者资格

IF 5 3区医学

Seminars in hematology Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.07.001

Neha Akkad , Dai Chihara

引用次数: 0